

CLAIMS AMENDMENT

1-71. (Canceled)

72. (Currently amended): A method of ~~modulating cells that express inhibiting 19P1E8 activity, the method comprising:~~

~~administering to the cells a cell that express expresses 19P1E8 an altering an effective amount of a composition capable of inhibiting 19P1E8 activity, whereby the composition alters the status of 19P1E8 or alters the status of a molecule that is modulated by inhibits 19P1E8 binding or inhibits expression of 19P1E8 from the cell;~~

~~wherein 19P1E8 encodes a protein having at least 90% identity to SEQ ID NO: 2, whereby cells that express 19P1E8 are modulated.~~

73-79. (Canceled)

80. (Currently amended): A method of treating a subject, ~~which method comprises cells that express 19P1E8 by modulating said cells, the method comprising:~~

~~administering to the cells in vivo or ex vivo, an altering to the subject an effective amount of a composition capable of inhibiting 19P1E8 (SEQ ID NO: 2) activity to the subject, whereby the composition alters the status of 19P1E8 or alters the status of a molecule that is modulated by inhibits 19P1E8 binding or inhibits expression of 19P1E8;~~

~~wherein 19P1E8 encodes a protein having at least 90% identity to SEQ ID NO: 2.~~

~~whereby cells that express 19P1E8 are modulated and the subject receives some treatment effect.~~

81-89. (Canceled)

90. (Previously Presented): ~~A The method in accordance with of claim 72, wherein said administering is to cells ex vivo.~~

91. (Previously Presented): ~~A~~ The method ~~in accordance with~~ of claim 72, wherein said administering is to cells *in vivo*.

92. (New): The method of claim 80, wherein said administering is to cells *ex vivo*.

93. (New): The method of claim 80, wherein said administering is to cells *in vivo*.

94. (New): The method of claim 72, wherein the composition comprises an antibody that binds to 19P1E8.

95. (New): The method of claim 94, wherein the antibody is a monoclonal antibody.

96. (New): The method of claim 94, wherein the antibody is a polyclonal antibody

97. (New): The method of claim 94, wherein the antibody is a chimeric antibody.

98. (New): The method of claim 94, wherein the antibody is a humanized antibody.

99. (New): The method of claim 94, wherein the antibody comprises an antibody fragment selected from the group consisting of a Fab, a F(ab')2, a Fv and a sFv fragment.

100. (New): The method of claim 80, wherein the composition comprises an antibody that binds to 19P1E8.

101. (New): The method of claim 100, wherein the antibody is a monoclonal antibody.

102. (New): The method of claim 100, wherein the antibody is a polyclonal antibody

103. (New): The method of claim 100, wherein the antibody is a chimeric antibody.

104. (New): The method of claim 100, wherein the antibody is a humanized antibody.

105. (New): The method of claim 100, wherein the antibody comprises an antibody fragment selected from the group consisting of a Fab, a F(ab')2, a Fv and a sFv fragment.